The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Open accessAbstract
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescence induction by inhibition of DNA replication kinase CDC7 has also been paired with a senolytic that disrupts mTOR signaling, inducing apoptosis in senescent human liver cancer cells and improving survival in mouse models of HCC (Wang et al. 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Wang et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma30 and liver cancer31, ATP1B3 in gastric cancer32, and FKBP14 in ovarian cancer33.”
From Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature (2023) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model of liver cancer, the mTOR inhibitor AZD8055 also showed senolytic potential against cancer cells with senescence induced by small- molecule inhibitors of CDC7 (ref. 207 ) .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [207]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Elevated expression of p16 in melanocytes156 and epidermal and dermal cells157,158 is associated with human aging.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“Based on the preclinical experimental evidence enumerated here, approaches based on the induction of senescence in large fraction of tumors have the potential to enter the realm of the clinical practice, even more if combined with adjuvant immunotherapy or senolytic therapy to remove potentially harmful senescent escaper variants, as recently proposed.189,202,203”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationThe comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,845
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Cited by
Sorted by citations
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Senescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177
“For example, the SASP produced by preneoplastic hepatocytes recruits immature myeloid cells that inhibit NK cells, therefore contributing to HCC progression (Eggert et al. 2016).”
BackgroundSenolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Self-citationSenescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Self-citationTargeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 587
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
EGFR activation limits the response of liver cancer to lenvatinib
Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., et al. (2021) · Nature · doi:10.1038/s41586-021-03741-7 · Cited by 456
Self-citationMacrophages at the interface of the co-evolving cancer ecosystem
Kloosterman, D. J., & Akkari, L. (2023) · Cell · doi:10.1016/j.cell.2023.02.020 · Cited by 452
Self-citationGuidelines for minimal information on cellular senescence experimentation in vivo
Ogrodnik, M., Carlos Acosta, J., Adams, P. D., d’Adda di Fagagna, F., Baker, D. J., Bishop, C. L., Chandra, T., Collado, M., Gil, J., Gorgoulis, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.059 · Cited by 376
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G. S., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., van Deursen, J., Goronzy, J. J., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 359
Zhu, G., Tang, Z., Huang, R., Qu, W., Fang, Y., Yang, R., Tao, C., Gao, J., Wu, X., Sun, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00529-z · Cited by 352
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 343
Ohtani, N. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00197-8 · Cited by 329
A Senescence-Centric View of Aging: Implications for Longevity and Disease
Borghesan, M., Hoogaars, W. M. H., Varela-Eirin, M., Talma, N., & Demaria, M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.07.002 · Cited by 267
Yang, C. G., Huang, X., Yan, L., Chen, J., Lv, Y., & Dai, S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa164 · Cited by 269
Li, F., Huangyang, P., Burrows, M., Guo, K., Riscal, R., Godfrey, J. T., Lee, K. E., Lin, N., Lee, P., Blair, I. A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0511-2 · Cited by 216
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Ketamine Induces Ferroptosis of Liver Cancer Cells by Targeting lncRNA PVT1/miR-214-3p/GPX4
He, G., Bao, N. T. Y., Wang, S., Xi, M., Zhang, T.-H., & Chen, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s332847 · Cited by 209
Ge, T., Gu, X., Jia, R., Ge, S., Chai, P., Zhuang, A., & Fan, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12374 · Cited by 220
The Cancer SENESCopedia: A delineation of cancer cell senescence
Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L., Schepers, A., Wang, C., Jin, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109441 · Cited by 201
Self-citationCancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Self-citationRoles of extracellular vesicles in the aging microenvironment and age‐related diseases
Yin, Y., Chen, H., Wang, Y., Zhang, L., & Wang, X. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12154 · Cited by 205
Saleh, T., Carpenter, V. J., Tyutyunyk‐Massey, L., Murray, G., Leverson, J. D., Souers, A. J., Alotaibi, M. R., Faber, A. C., Reed, J., Harada, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12761 · Cited by 190
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F. M., & Shen, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00815-5 · Cited by 189
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Müller, M., Bird, T. G., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 182
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Kudlová, N., Sanctis, J. B. D., & Hajdúch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 186
Chambers, C. R., Ritchie, S., Pereira, B., & Timpson, P. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13042 · Cited by 182
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0405 · Cited by 144
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators
Tao, W., Yu, Z., & Han, J.-D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.009 · Cited by 147
When dormancy fuels tumour relapse
Santos-de-Frutos, K., & Djouder, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02257-0 · Cited by 153
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 146
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
Ferrín, G., Misas, M. G., Amado, V., Rodríguez‐Perálvarez, M., & de la Mata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041266 · Cited by 141
Zheng, C., Zhang, B., Li, Y., Liu, K., Wei, W., Liang, S., Guo, H., Ma, K., Liu, Y., Wang, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206798 · Cited by 137
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Chen, Y., Li, L., Lan, J., Cui, Y., Rao, X., Zhao, J., Xing, T., Ju, G., Song, G., Lou, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01466-9 · Cited by 126
Gao, Y. J., Hu, Y., Liu, Q., Li, X., Li, X., Kim, C., James, T. D., Li, J., Chen, X., & Guo, Y. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101278 · Cited by 125
Colucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 143
Cellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 128
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity
Sanfeliu-Redondo, D., Gibert-Ramos, A., & Gracia-Sancho, J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00913-4 · Cited by 117
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 111
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 113
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
Self-citationBiological functions of therapy-induced senescence in cancer
Fitsiou, E., Soto-Gamez, A., & Demaria, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.021 · Cited by 105
Therapy of Primary Liver Cancer
Feng, M., Pan, Y., Kong, R., & Shu, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100032 · Cited by 102
Hu, Y., Xuefeng, Y., Shandong, W., & Jianhua, X. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.024 · Cited by 97
Dolgin, E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00750-1 · Cited by 95
Zhang, H., Li, J., Chen, Y., Wu, J., Wang, K., Chen, L., Wang, Y., Jiang, X., Liu, Y., Wu, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100472 · Cited by 95
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 100
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 102
Karabicici, M., Alptekin, S., Karagonlar, Z. F., & Erdal, E. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12916 · Cited by 101
CDC7-independent G1/S transition revealed by targeted protein degradation
Suski, J. M., Ratnayeke, N., Braun, M., Zhang, T., Strmiska, V., Michowski, W., Can, G., Simoneau, A., Śnioch, K., Cup, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04698-x · Cited by 92
Li, X., Qiu, W., Li, J., Chen, X., Hu, Y., Gao, Y. J., Shi, D., Li, X., Lin, H., Hu, Z., et al. (2020) · Chemical Science · doi:10.1039/d0sc01234c · Cited by 92
Yu, Z., Deng, P., Chen, Y., Liu, S., Chen, J., Yang, Z., Chen, J., Fan, X., Wang, P., Cai, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100759 · Cited by 91
Xue, M., Dong, L., Zhang, H., Li, Y., Qiu, K., Zhao, Z., Gao, M., Han, L., Chan, A., Li, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01526-9 · Cited by 93
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Jeon, H.-M., Kim, J., Cho, H. J., Lee, W. J., Nguyen, D., Kim, S. S., Oh, Y. T., Kim, H., Jung, C., Piñero, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.007 · Cited by 91
Zhang, F., Guo, J., Yu, S., Zheng, Y., Duan, M., Zhao, L., Wang, Y., Yang, Z., & Jiang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12591 · Cited by 100
Detection of senescence using machine learning algorithms based on nuclear features
Duran, I., Pombo, J., Sun, B., Gallage, S., Kudo, H., McHugh, D., Bousset, L., Barragan Avila, J. E., Forlano, R., Manousou, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45421-w · Cited by 85
Li, F., Liu, P., Mi, W., Li, L., Anderson, N. M., Lesner, N. P., Burrows, M., Plesset, J. B., Majer, A. D., Wang, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00671-3 · Cited by 92
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Tekle, G. E., Bernasocchi, T., Unni, A. M., Bertoni, F., Rossi, D., Rubin, M. A., & Theurillat, J.-P. P. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.009 · Cited by 89
Synthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 81
Digital image analysis improves precision of PD ‐L1 scoring in cutaneous melanoma
Koelzer, V. H., Gisler, A., Hanhart, J., Griss, J., Wagner, S. N., Willi, N., Cathomas, G., Sachs, M., Kempf, W., Thommen, D. S., et al. (2018) · Histopathology · doi:10.1111/his.13528 · Cited by 71
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies
Saleh, T., Carpenter, V. J., Bloukh, S., & Gewirtz, D. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.010 · Cited by 70
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Liu, Y., Lomeli, I., & Kron, S. J. (2024) · Cells · doi:10.3390/cells13151281 · Cited by 74
Wang, H., Yuan, S., Zheng, Q., Zhang, S., Zhang, Q., Ji, S., Wang, W. J., Cao, Y., Guo, Y., Yang, X., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.025 · Cited by 67
Self-citationMa, Y., Chai, N., Jiang, Q., Chang, Z., Chai, Y., Li, X., Sun, H., Hou, J., & Linghu, E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105071 · Cited by 63
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition
Rahman, M., Olson, I., Mansour, M. A., Carlstrom, L. P., Sutiwisesak, R., Saber, R., Rajani, K. R., Warrington, A. E., Howard, A., Schroeder, M. A., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0029 · Cited by 67
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Wang, L., Jin, H., Jochems, F., Wang, S., Lieftink, C., Martinez, I. M., Conti, G. D., Edwards, F., de Oliveira, R. L., Schepers, A. G., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00462-2 · Cited by 68
Self-citationWang, K., Jiang, X., Jiang, Y., Liu, J., Du, Y., Zhang, Z., Li, Y., Zhao, X., Li, J., & Zhang, R. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02855-2 · Cited by 63
Malaquin, N., Vancayseele, A., Gilbert, S., Antenor-Habazac, L., Olivier, M., Brahem, Z. A. A., Fred Saad, C., Delouya, G., & Rodier, F. (2020) · Cells · doi:10.3390/cells9071593 · Cited by 60
Cellular Senescence in Liver Disease and Regeneration
Ferreira-González, S., Rodrigo‐Torres, D., Gadd, V. L., & Forbes, S. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1722262 · Cited by 60
Senescence under appraisal: hopes and challenges revisited
Davan-Wetton, C. S. A., Pessolano, E., Perretti, M., & Montero‐Melendez, T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03746-x · Cited by 61
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 61
Sauer, S. J., Reed, D. R., Ihnat, M. A., Hurst, R. E., Warshawsky, D., & Barkan, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659963 · Cited by 59
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58
Self-citationCarpenter, V. J., Saleh, T., Lee, S. M., Murray, G. F., Reed, J. C., Souers, A. J., Faber, A. C., Harada, H., & Gewirtz, D. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114765 · Cited by 57
Trustworthy multi-phase liver tumor segmentation via evidence-based uncertainty
Hu, C., Xia, T., Cui, Y., Zou, Q., Wang, Y., Xiao, W., Ju, S., & Li, X. (2024) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2024.108289 · Cited by 53
Oxidative stress and cellular senescence: Roles in tumor progression and therapeutic opportunities
Jin, P., Feng, X., Huang, C., Li, J., Wang, H. Z., Wang, X., Li, L., & Ma, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.70007 · Cited by 57
Luo, J., Sun, T., Liu, Z., Liu, Y., Liu, J., Wang, S., Shi, X., & Zhou, H. (2025) · International Journal of Oral Science · doi:10.1038/s41368-025-00380-w · Cited by 61
Zheng, K., Ma, J., Wang, Y., He, Z., & Deng, K. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201901231 · Cited by 52
Senescent cells in cancer therapy: why and how to remove them
Zhang, J., Zhang, D., & Yu, B. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.002 · Cited by 52
Lv, X., Yu, H., Zhang, Q., Huang, Y., Hong, X., Yu, T., Lan, H., Mei, C., Zhang, W., Luo, H., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15693 · Cited by 50
Liu, P., Tang, Q., Chen, M., Chen, W., Lu, Y., Liu, Z., & He, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589908 · Cited by 50
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Dang, F., Nie, L., Zhou, J. R., Shimizu, K., Chu, C., Wu, Z., Fassl, A., Ke, S., Wang, Y., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25700-6 · Cited by 52
Du, M., Sun, L., Guo, J. J., & Lv, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107198 · Cited by 51
Nutrient-delivery and metabolism reactivation therapy for melanoma
Chen, Y., Wang, C., Wu, Y., Wang, Y., Meng, Y. F., Wu, F., Zhang, H., Cheng, Y. Y., Jiang, X., Shi, J., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01690-6 · Cited by 48
Self-citationThinking Differently about Cancer Treatment Regimens
Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 52
Self-citationDalisay, D. S., Tenebro, C. P., Sabido, E. M., Suarez, A. F. L., Paderog, M. J. V., Reyes-Salarda, R., & Saludes, J. P. (2024) · Marine Drugs · doi:10.3390/md22030114 · Cited by 53
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 50
Chen, D., Wang, J., Li, Y., Xu, C., Meng, F., Zhang, P., & Liu, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1418 · Cited by 46
Hu, F., Zhang, R., Guo, W., Yan, T., He, X., Hu, F., Ren, F., Ma, X., Lei, J., & Zheng, W. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00321 · Cited by 47
González-Meljem, J. M., & Martínez-Barberá, J. P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03798-7 · Cited by 48
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
Zhu, X., Fu, Z., Dutchak, K., Arabzadeh, A., Milette, S., Steinberger, J., Morin, G., Monast, A., Pilon, V., Kong, T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1749 · Cited by 46
Metadata
- Authors
- Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., du Chatinier, A., Wang, L., Gao, D., Evers, B., Jin, G., Xue, Z., Schepers, A., Jochems, F., Sanchez, A. M., Mainardi, S., te Riele, H., Beijersbergen, R. L., Qin, W., Akkari, L., & Bernards, R.
- Affiliations
- Shanghai Jiao Tong University (CN)
- The Netherlands Cancer Institute (NL)
- Fudan University (CN)
- Corresponding author
- Qin, Wenxin
- Akkari, Leila
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2019-10-02
- Volume
- 574
- Issue
- 7777
- Pages
- 268-272
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6858884
- OpenAlex
- W2977409903
- Cited by
- 427
- References
- 31
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 85 · 2023: 64 · 2022: 66 · 2021: 67 · 2020: 63
- FWCI
- 33.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- hepatocellular carcinoma, liver cancer, senescence, senolysis, TP53 mutation, sertraline, mTOR signaling, apoptosis, drug combination therapy, kinome screen, antidepressant repurposing
- MeSH terms
- Animals, Disease Models, Animal, Female, Liver Neoplasms, Male, Mice, Inbred BALB C, Mutation, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Sertraline, Cell Line, Tumor, Mice, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
